Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1077 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-05-01

Study Completion Date

2018-09-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prognostic assessment after preoperative systemic therapy (PST) plays a vital role in breast cancer patients. The clinical-pathologic staging system incorporating estrogen receptor (ER)-negative disease and nuclear grade 3 tumor pathology (CPS+EG staging system) can effectively predict prognosis after PST. The Neo-Bioscore has been developed by the incorporation of the human epidermal growth factor receptor 2 (HER2) status into the CPS+EG staging system. But in a real world in China, the both staging systems had limits because of trastuzumab administration varied a lot in China from the United States. This retrospective study will validate CPS+EG and Neo-Bioscore system and explored a modified Neo-Bioscore system in multiple centers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.

NCT02773784

Invasive Breast Cancer

COMPLETED

Molecular Signature for Breast Cancer

NCT05724407

Breast Cancer

UNKNOWN

Clinical Value of Next Generation Sequencing in Endocrine Therapy for Advanced Hormone Receptor Positive/HER-2 Negative Breast Cancer

NCT03786575

Breast Neoplasm Female Therapeutics Mutation

UNKNOWN NA

Research on the Potential Mechanisms Underlying the Efficacy Differences in Specific Neoadjuvant Treatment Regimens for Different Subtypes of Breast Cancer

NCT07012720

Breast Cancer

RECRUITING NA

Innovative "Scoring System" in Breast Cancer Post Neoadiuvant Chemotherapy

NCT05213403

Early Breast Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Neoadjuvant Therapy Neoplasm Staging Estrogen Receptor Histological Grade HER2 Prognosis Predictive Value of Tests

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

A patient will be eligible for inclusion in this study if he or she meets all of the following criteria:

1. Has operable, histologically confirmed, Stage I, IIA, IIB, IIIA, IIIB or IIIC invasive carcinoma of the breast.
2. Has had neoadjuvant chemotherapy before operation for this breast cancer.
3. Age \>=18 to \<=75 years old.
4. Has known ER and PR status.
5. Has known HER-2 status.
6. Has known menopausal status.
7. Before PST, Lymph nodes were evaluated by fine needle biopsy (FNB) if the clinically positive, or by sentinel lymph nodes biopsy (SLNB) if the clinically or FNB negative.
8. Has complete surgical resection of the primary breast tumor after PST: either lumpectomy or mastectomy with sentinel lymph node biopsy or axillary dissection, with clear margins for both invasive and ductal carcinoma in situ (DCIS).
9. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
10. Has laboratory values of

* White blood cell count \>3000/mm3
* Absolute neutrophil count (ANC) ≥1500/mm3
* Hemoglobin ≥9.0 g/dL
* Total bilirubin \<ULN
* Serum creatinine ≤1.5 mg/dL
* Platelet count ≥100,000/mm3
* ULN = upper limit of normal
11. Has aspartate aminotransferase (AST) or alanine aminotransferase (ALT) and alkaline phosphatase (ALP) within any of the ranges shown below:

* ALP ≤ upper limits of normal(ULN),and AST or ALT ≤ 5 ULN
* ULN \< ALP ≤2.5 ULN, and AST or ALT ≤ 1.5 ULN
* 2.5 ULN \< ALP ≤5 ULN, and AST or ALT ≤ ULN
12. Has normal cardiac function as evidenced by an left ventricular ejection fraction (LVEF) \>50% by echocardiogram (ECHO), Ejection fraction as determined by ECHO must be within normal limits (WNL) by institutional standard.
13. Has no evidence of metastatic disease outside of breast by physical examination and chest x-ray or computed tomography (CT) scan. Other scans if done as needed by the patient \[e.g., bone scan; abdominal, chest CT; Positron Emission Tomography (PET) or Positron Emission Tomography-Computed Tomography (PET-CT); ultrasound; or Magnetic Resonance Imaging (MRI)\] should indicate no evidence of metastatic disease.
14. Has had baseline bilateral B-type ultrasound，MRI was recommended, but not essential.
15. If fertile, patient has agreed to use an acceptable method of birth control (barrier contraceptive only) to avoid pregnancy duration the study and for a period of 3 months thereafter

Exclusion Criteria

A patient will be excluded from this study if she meets any of the following criteria:

1. Has bilateral synchronous breast cancer.
2. Has any evidence of metastatic disease: staging work-up, biopsy or physical examination suspicious for malignant disease.
3. Has a history of severe hypersensitivity reaction to chemotherapy drugs or formulation.
4. Has a history of heart failure, uncontrolled angina, severe uncontrolled arrhythmias, pericardial disease, or electrocardiographic evidence of acute ischemic changes.
5. Has peripheral neuropathy \>Grade 1.
6. Has had a major organ allograft or condition requiring chronic immunosuppression (ie, kidney, liver, lung, heart, bone marrow transplant, or autoimmune diseases). Patients who have received corneal transplants or cadaver skin or bone transplants are eligible.
7. Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious viral \[including clinically defined acquired immune deficiency syndrome (AIDS)\], bacterial or fungal infection; or history of uncontrolled seizures, or diabetes, or central nervous system (CNS) disorders deemed by the Treating Physician to be clinically significant, precluding informed consent.
8. Has active hepatitis B or hepatitis C with abnormal liver function tests (LFTs) or is known to be human immunodeficiency virus (HIV) positive.
9. Has a history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin, carcinoma in situ of uterine cervix, DCIS), which could affect the diagnosis or assessment of any of the study drugs.
10. Is deemed unable to comply with requirements of study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No